PHOENIX–(BUSINESS WIRE)–Kerecis®pioneering use of fish skin and fatty acids in cell therapy, tissue regeneration and protection, MariGen announced today™ Expanse, the newest addition to Kerecis’ product offering for chronic wound management. The announcement was made at the Symposium for Advanced Wound Care (SAWC) meeting, taking place at the Phoenix Convention Center from April 6-10, 2022. Kerecis is exhibiting at booth 325.
This pre-mesh intact fish skin graft promotes healing and tissue regeneration in large chronic wounds, especially wounds 100 square centimeters (15.5 square inches) and larger that are treated in an outpatient setting . MariGen Expanse is an extension of Kerecis’ MariGen product line, which has been used to successfully treat tens of thousands of patients, prevent multiple amputations and improve the quality of life of many people around the world.
“Ambulatory wound care centers need to treat large chronic wounds effectively and economically,” said Fertram Sigurjónsson, founder and CEO of Kerecis. “MariGen Expanse fills this need and enables these wound care providers to help people with debilitating wounds.”
MariGen Expanse is now available in two pre-mesh sizes: 7×8 centimeters (3×3 inches) and 8×10 centimeters (3×4 inches). Thanks to its 2:1 mesh, the product can be stretched to cover up to 101 and 144 square centimeters (15 and 22 square inches) respectively.
“Large leg ulcers, which are sometimes circumferential, are difficult to heal with limited care options due to their size,” said Dr. Lisa Dadson, DMP. “Within a week of first application of MariGen Expanse to a large venous leg ulcer, I noticed a decrease in wound size. There was reduced drainage with less redness and swelling. The patient also reported a reduction in pain.
Kerecis Intact Fish Skin Technology
Kerecis products are based on fatty acid-rich intact fish skin which, when grafted onto damaged human tissue, recruits the body’s own cells and is ultimately converted into living tissue. Because there is no risk of disease transfer between cold water fish and humans, Kerecis fish skin is only gently processed and retains its similarity to human tissue. The gentle treatment preserves the original three-dimensional structure of the skin and maintains the strength, complexity and natural molecules inherent in the skin (such as omega3 and other fatty acids). Clinical studies have shown that Kerecis products heal wounds faster than other products.
In addition to the new product MariGen, the company offers three other product lines. GraftGuide deals with the management of burns; and SurgiClose and SurgiBind are designed to close surgical gaps.
Kerecis develops products based on fish skin and fatty acids for cell therapy, tissue regeneration and protection. The intact fish skin of Kerecis protects the body’s tissues and allows it to regenerate tissues. Kerecis topical and oral spray formulations protect the body against bacterial and viral infections.
Kerecis is the only licensed manufacturer of medical devices containing intact fish skin in the world. According to SmartTRAK Business Intelligence, it is the fastest growing company and one of the top eight in the US skin and biologic skin substitute market.
Kerecis is committed to the United Nations Sustainable Development Goals. The fish skin used in Kerecis products comes from wild, sustainable fish stocks caught in pristine Icelandic waters and processed with 100% renewable energy in the town of Isafjordur, near the Arctic Circle. For more information, visit https://www.kerecis.com.